205 related articles for article (PubMed ID: 31348591)
1. Cancer therapy with major histocompatibility complex-deficient and interferon β-producing myeloid cells derived from allogeneic embryonic stem cells.
Umemoto S; Haruta M; Sakisaka M; Ikeda T; Tsukamoto H; Komohara Y; Takeya M; Nishimura Y; Senju S
Cancer Sci; 2019 Oct; 110(10):3027-3037. PubMed ID: 31348591
[TBL] [Abstract][Full Text] [Related]
2. Therapy of peritoneally disseminated colon cancer by TAP-deficient embryonic stem cell-derived macrophages in allogeneic recipients.
Haga E; Endo Y; Haruta M; Koba C; Matsumura K; Takamatsu K; Ikeda T; Nishimura Y; Senju S
J Immunol; 2014 Aug; 193(4):2024-33. PubMed ID: 25031460
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models.
Koba C; Haruta M; Matsunaga Y; Matsumura K; Haga E; Sasaki Y; Ikeda T; Takamatsu K; Nishimura Y; Senju S
PLoS One; 2013; 8(6):e67567. PubMed ID: 23826321
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell-derived myelomonocytic cells producing interferon beta.
Imamura Y; Tashiro H; Tsend-Ayush G; Haruta M; Dashdemberel N; Komohara Y; Tsuboki J; Takaishi K; Ohba T; Nishimura Y; Katabuchi H; Senju S
Cancer Sci; 2018 Nov; 109(11):3403-3410. PubMed ID: 30142694
[TBL] [Abstract][Full Text] [Related]
5. Activation of antigen-specific cytotoxic T lymphocytes by beta 2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells.
Matsunaga Y; Fukuma D; Hirata S; Fukushima S; Haruta M; Ikeda T; Negishi I; Nishimura Y; Senju S
J Immunol; 2008 Nov; 181(9):6635-43. PubMed ID: 18941254
[TBL] [Abstract][Full Text] [Related]
6. Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-β.
Sakisaka M; Haruta M; Komohara Y; Umemoto S; Matsumura K; Ikeda T; Takeya M; Inomata Y; Nishimura Y; Senju S
J Hepatobiliary Pancreat Sci; 2017 Feb; 24(2):109-119. PubMed ID: 28008721
[TBL] [Abstract][Full Text] [Related]
7. Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression.
Magliocca JF; Held IK; Odorico JS
Stem Cells Dev; 2006 Oct; 15(5):707-17. PubMed ID: 17105406
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with 4-1BBL-Expressing iPS Cell-Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma.
Kuriyama H; Fukushima S; Kimura T; Kanemaru H; Miyashita A; Okada E; Kubo Y; Nakahara S; Tokuzumi A; Nishimura Y; Kajihara I; Makino K; Aoi J; Masuguchi S; Tsukamoto H; Inozume T; Zhang R; Nakatsura T; Uemura Y; Senju S; Ihn H
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669419
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation.
Hara H; Kobayashi A; Narumi K; Kondoh A; Yoshida K; Nishimoto T; Ohashi M; Higashihara E; Ohnami S; Yoshida T; Aoki K
Cancer Immunol Immunother; 2009 Jul; 58(7):1007-21. PubMed ID: 18998126
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
[TBL] [Abstract][Full Text] [Related]
11. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells.
Haruta M; Tomita Y; Yuno A; Matsumura K; Ikeda T; Takamatsu K; Haga E; Koba C; Nishimura Y; Senju S
Gene Ther; 2013 May; 20(5):504-13. PubMed ID: 22875043
[TBL] [Abstract][Full Text] [Related]
12. Expression of major histocompatibility complex class I proteins and their antigen processing chaperones in mouse embryonic stem cells from fertilized and parthenogenetic embryos.
Lampton PW; Crooker RJ; Newmark JA; Warner CM
Tissue Antigens; 2008 Nov; 72(5):448-57. PubMed ID: 18778324
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer.
Li Y; Zeng H; Xu RH; Liu B; Li Z
Stem Cells; 2009 Dec; 27(12):3103-11. PubMed ID: 19816950
[TBL] [Abstract][Full Text] [Related]
14. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
15. New Immunosuppressive Cell Therapy to Prolong Survival of Induced Pluripotent Stem Cell-Derived Allografts.
Sasaki H; Wada H; Baghdadi M; Tsuji H; Otsuka R; Morita K; Shinohara N; Seino K
Transplantation; 2015 Nov; 99(11):2301-10. PubMed ID: 26360665
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization and engraftment of adipocytes derived from human induced pluripotent stem cells and embryonic stem cells.
Noguchi M; Hosoda K; Nakane M; Mori E; Nakao K; Taura D; Yamamoto Y; Kusakabe T; Sone M; Sakurai H; Fujikura J; Ebihara K; Nakao K
Stem Cells Dev; 2013 Nov; 22(21):2895-905. PubMed ID: 23750558
[TBL] [Abstract][Full Text] [Related]
17. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy against Metastatic Melanoma with Human iPS Cell-Derived Myeloid Cell Lines Producing Type I Interferons.
Miyashita A; Fukushima S; Nakahara S; Kubo Y; Tokuzumi A; Yamashita J; Aoi J; Haruta M; Senju S; Nishimura Y; Jinnin M; Ihn H
Cancer Immunol Res; 2016 Mar; 4(3):248-58. PubMed ID: 26714554
[TBL] [Abstract][Full Text] [Related]
19. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
Morrison BJ; Steel JC; Morris JC
BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
[TBL] [Abstract][Full Text] [Related]
20. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
